The capacity to tolerate and respond to cancer treatment can be impacted by renal impairment. In this phase 3 trial, researchers compared nab-paclitaxel to docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) and renal impairment. Before treatment, non-small cell lung cancer patients were divided into 2 groups and given either docetaxel (60 mg/m2) on day 1 or nab-paclitaxel (100 mg/m2) on days 1, 8, and 15 of a 21-day cycle. Treatment efficacy and safety were assessed about renal function.
Out of the 503 people who took part in the phase 3 trial, 17.3% had moderate renal impairment (creatinine clearance of ≤50 mL/min; n=49 for docetaxel and n=38 for nab-paclitaxel), and 53.1% had mild renal impairment (creatinine clearance of >50 to ≤80 mL/min; n=133 for docetaxel and n=134 for nab-paclitaxel Patients who had problems with their kidneys were less likely to get feverish neutropenia if they were in the nab-paclitaxel group than if they were in the docetaxel group.
Patients with moderate or mild renal impairment showed no significant difference in treatment efficacy between nab-paclitaxel and docetaxel, similar to the whole study population. However, patients with advanced NSCLC and mild to severe renal impairment previously treated have been shown to benefit from and tolerate nab-paclitaxel.